Top 50 Pharma Tracker: HCPs celebrate a successful quarter for oncology and obesity treatments

16.01.2025 | Tracker

Top 50 Pharma Tracker: HCPs celebrate a successful quarter for oncology and obesity treatments

The Top 50 Pharmaceutical Companies mentioned by HCPs on X

Current Quarter
Rank
Previous Quarter
Rank
Company
Name
Total
Mentions
Account
Mentions
Account
Retweets
11Pfizer8,8826419
22Moderna3,8672369
34Johnson & Johnson1,8773464
46AstraZeneca1,28951746
53Novavax1,20619112
65GSK1,16029752
77Novo Nordisk1,09360141
814Lilly1,0376761
912Sanofi83722448
108Roche68230854
1110Gilead Sciences56423010
1211Merck & Co50415623
1313Abbott47545228
1416AbbVie47234168
159Bayer4521398
1617Novartis40521316
1720Amgen32423511
1815Boehringer Ingelheim2181823
1924Takeda2051940
2028Daiichi Sankyo2008530
2118Otsuka179100
2233Teva1491102
2319BMS145953
2426Organon13980
2521Fresenius1205612
2623Chugai11055
2722Regeneron81413
2825Astellas73461
2931STADA Arneimittel7040
3028UCB665622
3136Servier655529
3233Merck KGaA615613
3337Ipsen58410
3440Viatris5230
3530Biogen45230
3632Vertex44441
3742Menarini32265
3744Jazz Pharmaceuticals32191
3933Eisai31194
4026Dr. Reddy's Labratories3070
4145Grifols2720
4239CSL26230
4240Bausch2691
4443Incyte18160
4538Sun621
4650Shanghai300
5046Jiangsu Hengrui000
5050Sino000
5050Yunnan Baiyao Group000
5050Mitsubishi Chemical Group000

2024 Q4’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies

The five most mentioned pharmaceutical companies by HCPs on X between October and December 2024 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax.Top-5-companies-mentioned

CREATION.co identified 23,806 HCP mentions of pharmaceutical companies between October and December 2024, an increase of 9.43% compared to the previous quarter.

Oncology developments

On 08 October, Surgeon Bryan Bell shared a press release from Merck regarding the KEYNOTE-689 trial, which evaluated pembrolizumab for the treatment of locally advanced head and neck squamous cell carcinoma. According to the surgeon, this is “a disease that has not seen meaningful change in treatment in 40 years”. He finishes the post by congratulating Merck for the trial results, expressing his excitement for a potential new treatment paradigm.

The news of the successful clinical trial resonated with his HCP peers, with 6 of them sharing his post.

In the world of prostate cancer, other exciting news for clinical trials has emerged. On 25 November, genitourinary (GU) oncologist María Natalia Gandur Quiroga wrote a post highlighting AstraZeneca’s CAPItello-281 trial. The post highlighted a few of the important developments, including a consistent safety profile with other medications, significant improvements in radiographic progression-free survival, and a step forward in addressing patient needs. She calls the results of the trial “exciting news in prostate cancer!”

The news of the clinical trial also caught the attention of GU Digital Opinion Leader (DOL) Toni Choueiri, tagging AstraZeneca in his post and sharing the press release.

The positive news of AstraZeneca’s trial was well received, with almost 40 HCPs online sharing the news.

On 30 November, breast cancer DOL Paolo Tarantino shared a post ahead of the San Antonio Breast Cancer Symposium (SABCS) 2024 where he stated his excitement for presenting research of four studies. He thanked his partners and colleagues for their collaboration, including Novartis, calling them “brilliant”.

Obesity and weight loss developments

On 25 October, Type 2 Diabetes DOL Daniel Drucker shared a post about the weight loss space, calling the ongoing competition between competitors “a strong start”. He highlighted the innovation that has happened which has allowed more patients to get access to these treatments. He tagged many pharmaceutical companies including Novo Nordisk, Eli Lilly, Amgen, Roche and Pfizer.

On 01 November, Type 2 Diabetes DOL Cristobal Morales shared a press release from Novo Nordisk regarding the ESSENCE trial, evaluating semaglutide’s efficacy in treating liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). He quotes the press release, highlighting the “superior improvement” that semaglutide had in both diseases.

Shared by 18 HCPs

The second most shared post discussing the ESSENCE trial when discussing a pharmaceutical company was from physician Manuel Romero-Gómez, who called this the “last piece in a perfect puzzle”. His post was shared by 4 HCPs, compared to Cristobal Morales who received 18 shares by his HCP peers.

 

On 04 December, DOL Daniel Drucker returned to the weight loss conversation by sharing the results of the SURMOUNT-5 trial which demonstrated higher efficacy of tirzepatide compared to semaglutide. He stated that in this race of weight loss treatments, “tirzepatide notches a win”.

 

A few weeks later, Daniel Drucker jumped back into the weight loss conversation again on 20 December to share the press release from Novo Nordisk that reported on the results from the REDEFINE-1 trial, tagging Novo Nordisk in his post.

Daniel Drucker’s was shared by 13 HCPs. The REDEFINE-1 trial also caught the attention of DOL Cristobal Morales who also shared the news. His post also resonated with HCP peers globally, with 11 HCPs sharing his post about the REDEFINE-1 trial – becoming the second most shared HCP post about the trial when mentioning a pharmaceutical company.

Other developments

On 06 October, the Options 2024 conference took place, where HCPs gathered to discuss the detection, treatment and control of influenza and other respiratory diseases. Physician Raina MacIntyre posted from the conference, calling it a “pleasure to talk about #influenza and #cardiovascular disease at the @sanofi symposium”.

Between 16 and 18 November, the American Heart Association AHA) 2024 congress took place in Chicago, Illinois. At the congress HCPs gathered to discuss the latest developments in the field of cardiovascular diseases and cardiology, discussing treatment options, scientific developments and networking with peers. On 17 November, Professor Maciej Banach posted from the Amgen booth with his peers about a network of “#lipid #fighters”, calling it an “amazing initiative” from Amgen.

On 22 November, cardiologist Annabelle Volgman thanked BMS, Gilead and Amgen for their work in programs to enhance clinical trial diversity. She stated that she was “so impressed” with the cohort and congratulated her peers for winning the “Robert A. Winn Excellence in Clinical Trials Awards”

 

Should pharmaceutical companies listen to online HCPs?

Over the last quarter, HCPs celebrated online when pharmaceutical companies reached endpoints to cancer treatment trials, supported initiatives to address the disparity in clinical trial diversity and worked on treatment options that provide more options to patients.

The top shared links by HCPs when mentioning a Top 50 pharma company discussed:

  1. A journal article about Novavax’s COVID-19 vaccine side effects compared to competitors.
  2. A link to Novo Nordisk’s press release site.
  3. A PDF download of a nephrology publication sponsored by AstraZeneca.

It’s clear that many HCPs rely on social media to discover and share new medical science. As well as being amplifiers and disseminators of new science, their collective and individual voices provide a powerful guide to how physicians think new treatments will shape patient care now and in the future. 

By listening to the online voice of healthcare professionals, medicine manufacturers can discover what’s important to physicians on the front lines of patient care, find out whether their messaging about new medicines is resonating, and predict future HCP behaviours.

At CREATION.co, we’ve been tracking the online HCP voice for over a decade, thanks to our specialist technology platform, CREATION Pinpoint. Talk with us about how our insights can inspire your next innovation.

——

Find out how the conversation is changing in other Top 50 Trackers and new analysis of the online HCP conversation in a variety of topics

You can also receive these updates and more straight to your inbox by signing up to CREATION.co’s monthly eJournal.

Methodology notes:

    • In October – December 2024, CREATION Pinpoint® identified 23,806 posts on X (Twitter) from 7,224 individual HCPs mentioning a Top 50 Pharmaceutical company (based on revenue). 
    • Data for this research was analysed from the online X conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 September – 31 December 2024.
  • Unless otherwise specified, mentions of a company are not limited to its X account(s).
  • In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
  • Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In October  – December 2024, 187 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.

 

 

Share this article

Meet the Author

Aman Jandu

With a background working in IT systems administration, and leveraging a 1st Class degree in Digital Technologies, Aman uses his technical skills to apply a systematic approach to gather data and analyse insights.

Aman loves to Speedcube. While he can currently solve a Rubik’s Cube in around 20 seconds, he is learning how to complete it blindfolded.

Suggested next


01.10.2023 | Article

Top 50 Pharma Tracker: eHCPs celebrate vaccine data from Novavax and Moderna approval

Discover what healthcare professionals (HCPs) think about pharmaceutical companies

By Aman Jandu

15.07.2020 | Article

Quieter ASCO for pancreatic cancer

Declines in online pancreatic cancer conversations healthcare professionals from ASCO 2020

By Jamie Doggett

View all articles >